DIRS.INFO The most relevant business & tech news

☆ Here's what Wall Street is saying about obesity drug Wegovy following Novo Nordisk's key study
▼ + stars: | 2023-11-13 | by ( Alex Harring | ) www.cnbc.com time to read: +6 min

Wegovy contains semaglutide, the same active ingredient in Novo's type 2 diabetes drug Ozempic. A rising tide for Eli Lilly? Though the study was specifically about Wegovy, Wall Street sees a positive readthrough for similar medications from other providers, particularly Eli Lilly 's Zepbound. Similarly, UBS analyst Trung Huynh called the weekend data a "best-case" scenario for Eli Lilly. And the positive outcomes for both in the Wegovy study can be viewed as encouraging for how Zepbound should perform, the analyst added.

Persons: Morgan Stanley, Mark Purcell, Richard Vosser, Peter Verdult, Eli Lilly, Eli Lilly's, Lilly, Andrew Baum, Trung Huynh, That's, it's, Zepbound, Huynh, Citi's Baum, James Shin isn't, Michael Bloom, Christina Cheddar Berk, Angelica Peebles Organizations: Novo Nordisk, American Heart Association, cardiologists, JPMorgan, Citi, ., UBS, North American, Tandem Diabetes Care, Deutsche Bank

☆ Trial confirms heart benefits of Wegovy, but is weight loss responsible – or something else?
▼ + stars: | 2023-11-11 | by ( Meg Tirrell | ) edition.cnn.com time to read: +9 min

To cardiologist Dr. Steven Nissen of the Cleveland Clinic, who wasn’t involved in the trial but is leading a similar one of tirzepatide, those effects are all evidence of the benefits of weight loss. Tirzepatide has shown greater levels of weight loss than semaglutide in clinical trials, leading many, including Nissen, to hope it will show even stronger cardiovascular benefits. Importantly, participants didn’t have a history of diabetes; a previous trial had shown that treating people with diabetes with a GLP-1 drug, Ozempic, reduced their cardiovascular risk. The Wegovy trial showed that 569 of 8,803 people taking the drug had a heart attack or stroke or died from heart-related causes, or 6.5%. The amount of weight loss seen in the trial, 9.4%, was less than in other studies of Wegovy, which showed average weight loss closer to 15%.

Persons: Ania Jastreboff, Wegovy, Dr, Amit Khera, National Institutes of Health’s Dr, Tiffany M, Powell, Wiley, Eli Lilly, Steven Nissen, wasn’t, ” Nissen, “, Tirzepatide, Nissen, Michael Lincoff, Lincoff, ”, Jastreboff, Sanjay Gupta, hadn’t, “ semaglutide Organizations: CNN, Nordisk’s Wegovy, American Heart Association, Yale Obesity Research Center, University of Texas Southwestern Medical Center Dallas, National Institutes of Health’s, New England, of Medicine, US Food and Drug, Cleveland Clinic, Novo Nordisk, Cleveland, CNN Health Locations: Philadelphia, Powell

☆ AstraZeneca adds player to obesity drug race, but Eli Lilly remains in the lead
▼ + stars: | 2023-11-10 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +8 min

Eli Lilly (LLY) remains our favorite way to play the weight-loss drug market, despite a new entry this week from AstraZeneca (AZN). Eli Lilly shares had their worst day of the year Thursday, falling 4.5% in the session to close at $591.32. AstraZeneca's encroachment on turf currently dominated by Eli Lilly and Danish rival Novo Nordisk (NVO) may have contributed to Thursday's declines. That approval, despite being widely expected, pushed Eli Lilly to an all-time closing high Wednesday, at $619.13 per share. Our desire to own Eli Lilly over Novo Nordisk hinges, in part, on our confidence in Eli Lilly's other treatment opportunities, such as in Alzheimer's.

Persons: Eli Lilly, Jim Cramer, Jim, Lilly's, Eli Lilly's tirzepatide, Zepbound, Novo's, Eli Lilly's, Eli Lilly's GLP, Dave Ricks, Lilly, Ricks, AstraZeneca's, ECC5004, retatrutide, Jim Cramer's, David Ricks, Eli Lilly Scott Mlyn Organizations: AstraZeneca, Novo Nordisk, American Heart Association, Novo Nordisk's semaglutide, CNBC, Reuters, Citigroup Locations: Danish, GLP, North Carolina, Novo, Denmark, Zepbound, Alzheimer's

☆ Lilly trades at a premium to Ozempic-maker Novo as obesity drugs boom. Here's why, analyst says
▼ + stars: | 2023-11-10 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +6 min

Does Eli Lilly deserve to trade at a premium to Novo Nordisk shares? LLY YTD mountain Eli Lilly shares since the start of the year. According to Shin, Lilly deserves a premium to Novo Nordisk because its portfolio is more diverse and it has less exposure to insulin. NVO YTD mountain Novo Nordisk shares year to date In the coming weeks, Lilly will start rolling out Zepbound to patients. Novo Nordisk is scheduled to release the full results of its Select cardiovascular trial at the American Heart Association conference.

Persons: Eli Lilly, James Shin, Shin, Lilly, We're, Lilly's, Zepbound, Wegovy, Chris Schott, Karsten Munk Knudsen, Novo, Schott, AstraZeneca, Eccogene, David Ricks, — CNBC's Michael Bloom Organizations: Novo Nordisk, Deutsche Bank, Biotech, Pharma, Centers for Disease Control, Novo, CNBC, American Heart Association Locations: U.S, GLP, Novo, Denmarkt

A 0.25 mg injection pen of Novo Nordisk's weight-loss drug Wegovy is shown in this photo illustration in Oslo, Norway, August31, 2023. The U.S. Food and Drug Administration on Wednesday said Eli Lilly (LLY.N) could begin selling its drug tirzepatide for weight loss, making it the second obesity drug in a class known as GLP-1s. Studies of Novo's Wegovy showed that it led to 15% weight loss over 68 weeks, while Lilly's drug, which also targets a second hormone called GIP, demonstrated weight loss of more than 22% over 72 weeks. Drugstore chain Walgreens is seeing "enormous demand" for GLP-1s, said John Driscoll, president, U.S. healthcare at Walgreens Boots Alliance (WBA.O). Much has been made of the impact the new weight loss drugs might have on consumer habits such as snack food purchases, but Driscoll said Walgreens has not seen that yet.

Persons: Victoria Klesty, Eli Lilly, Novo, Novo's Wegovy, Lawrence Tabak, John Driscoll, Tabak, Driscoll, Walgreens, Julie Steenhuuysen, Caroline Stauffer, Deena Beasley, Jamie Freed Organizations: REUTERS, Rights, Reuters, Total Health, U.S . Food, Drug Administration, U.S . National Institutes of Health, Walgreens, Walgreens Boots Alliance, Thomson Locations: Oslo, Norway, August31, Victoria, Chicago, U.S, satiety

A new version of the popular diabetes treatment Mounjaro can be sold as a weight-loss drug, U.S. regulators announced Wednesday. The U.S. Food and Drug Administration approved Eli Lilly's drug, named Zepbound. Zepbound is the latest diabetes drug approved for chronic weight management, joining Novo Nordisk's Wegovy, a high-dose version of its diabetes treatment Ozempic. Those with diabetes, who have a harder time losing weight, cut about 12%, or nearly 27 pounds (12 kilograms), the FDA said. Approved for weight loss in 2021, Wegovy helped people lose about 15% of their weight or 34 pounds (15 kilograms), according to study results.

Persons: Eli Lilly's, dieters, Zepbound, Wegovy, Fatima Cody Stanford, tirzepatide, pare, ”, Katherine Saunders, Eli Lilly, Mounjaro, Kelly Burns, Burns Organizations: U.S . Food, Drug Administration, Novo Nordisk's Wegovy, FDA, Massachusetts General Hospital, New York's Weill Cornell Medicine, Associated Press Health, Science Department, Howard Hughes Medical Institute’s Science, Educational Media Group, AP Locations: U.S, Zepbound, Wegovy, Massachusetts, Boston, St . Petersburg , Florida

☆ FDA approves Eli Lilly's tirzepatide for weight loss, paving way for wider use of blockbuster drug
▼ + stars: | 2023-11-08 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +6 min

George Frey | ReutersThe Food and Drug Administration on Wednesday approved Eli Lilly 's blockbuster drug tirzepatide for weight loss, paving the way for even wider use of the treatment in the U.S. The FDA said the approval was based on two of Eli Lilly's late-stage trials on tirzepatide, which evaluated its effects on weight loss after 72 weeks. Higher doses of the drug were associated with even more weight loss, with a 15-milligram dose leading to 22.5% weight loss on average. The bigger issue is that many insurance companies are dropping weight loss drugs from their plans. Preliminary data is already available: A recent late-stage trial found that Novo Nordisk's weight loss drug Wegovy reduced the risk of cardiovascular events such as heart attack and stroke by 20%.

Persons: George Frey, Eli Lilly, John Sharretts, Eli Lilly's, Wegovy, Lilly, Mike Mason, Eli Lilly Diabetes Organizations: Novo Nordisk, Pharmacy, Reuters, Food, Drug Administration, U.S, FDA's Center, Drug, FDA, Obesity Locations: Provo , Utah, U.S, United States

☆ Here are 5 anti-obesity drug stocks besides Novo Nordisk and Eli Lilly to watch into year-end
▼ + stars: | 2023-10-29 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +11 min

Novo Nordisk and Eli Lilly reign over the anti-obesity drug market, and don't expect this duopoly to end soon, analysts say. All this goes on amid robust demand for Novo's semaglutide, which is sold as Ozempic for type 2 diabetes and as Wegovy for weight loss, and Lilly's tirzepatide, which hopes to receive regulatory approval for weight loss this year. Orforglipron is an oral drug Eli Lilly is developing. It has several other compounds in the pipeline, but Suvannavejh expects the weight loss drug to receive increased attention. "This range would also be competitive with LLY's orforglipron [an oral GLP-1 drug] weight loss at day 28," Smith said.

Persons: Eli Lilly, Piper Sandler, Yasmeen Rahimi, Cantor Fitzgerald, Louise Chen, Lilly, Lilly's, Chen, Price, Kyle Rasbach, We've, Rasbach, Altimmune Altimmune, NASH, Piper's, Rahimi, Cantor's Chen, it's, Eli Lilly's Mounjaro, Goldman Sachs, Chris Shibutani, David Risinger, Risinger, Jonathan Wolleben, Wolleben, Orforglipron, Graig Suvannavejh, Suvannavejh, Thomas Smith, LLY's, Smith, Yale Jen, Jen Organizations: Novo Nordisk, Pfizer, Novo, pharma, Pfizer Pfizer, danuglipron, Therapeutics, Leerink, Mizuho Securities, Viking Therapeutics Viking Therapeutics, Laidlaw & Co Locations: Novo, GLP, Eventide

☆ These stocks are trying to solve a major shortcoming of weight loss drugs: Shrinking muscle mass
▼ + stars: | 2023-10-22 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +9 min

One of the downsides of taking new anti-obesity medications is that patients tend to lose lean muscle mass along with body fat. "This is a major shortcoming in terms of not just quality of life for the patients who have to lose lean muscle mass, but there's actually room to improve on the weight loss and there [are] other metabolic benefits to improving your lean muscle mass ... [including] you might have better durability of weight loss." The drug is being tested in a phase 2b study alongside semaglutide to protect against loss of muscle mass. Until then, patients will need to watch what they eat and focus on exercise just as they would on any other weight loss regimen. When that occurs, muscle loss will be an even bigger issue than it is now.

Persons: Piper Sandler, Allison Bratzel, there's, Bratzel, Versanis, Eli Lilly, Eli Lilly's Mounjaro, they're, Lydia Alexander, Alexander, Sandler's Bratzel, incretins, Biohaven, Nestle, Ulf Mark Schneider, Jeff Jonas, Jonas, Stephens, Jim Salera, Atkins, Morgan Stanley, — CNBC's Michael Bloom Organizations: Wall, Nordisk's Ozempic, Obesity Medicine Association, Bristol Myers Squibb, Nestle, Gabelli, Quest, Foods Locations: Swiss

☆ Analysts predicted new obesity medicines would be blockbusters. Now they’re raising their forecasts
▼ + stars: | 2023-09-16 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +9 min

Fernandez sees a total addressable market of $140 billion to support patients with obesity. He expects there is a potential for GLP-1 drugs to become as common and widely used, much like statins are used to lower cholesterol. Morgan Stanley's Flynn estimates a 30% share of the diabetes market would generate $109 billion on a worldwide basis for GLP-1 drugs. Layer in a 15% to 30% share of the obesity market and that equates to worldwide sales of $97.4 billion to $194.8 billion. Guggenheim's estimates also assume that oral GLP-1 drugs that are currently in development are able to come to market a few years from now.

Persons: Seamus Fernandez, Fernandez, Lilly, Eli Lilly, Morgan Stanley, Terence Flynn, Eli Lilly's Mounjaro, Insulet, Canaccord, William Plovanic, Plovanic, It's, Morgan Stanley's Flynn, Flynn, Novo, Michael Bloom Organizations: Wall, Novo, American Heart Association, Food and Drug Administration, Novo Nordisk, Iqvia, Disease Control Locations: GLP

☆ Big pharma's blockbuster obesity drug battle is just getting started, and it's headed for $100 billion
▼ + stars: | 2023-09-09 | by ( Bob Woods | ) www.cnbc.com time to read: +13 min

In this article LLYNOVO.B-DK Follow your favorite stocks CREATE FREE ACCOUNTOzempic drug to treat diabetes. Since Wegovy and Mounjaro have been on the market, "neither company can make the drug fast enough," she said. The Food and Drug Administration approved Ozempic in 2017 for diabetes and Wegovy in 2021 to treat obesity. Mounjaro, introduced in 2022 to treat diabetes, contains GLP-1, plus GIP, a similar appetite suppressor that can lead to weight loss. Coverage for Mounjaro ($1,023 per month) to treat diabetes varies based on an individual's insurance plan and drug benefits.

Persons: Eli Lilly, Novo's, Lilly's, Emily Field, Lilly, David Ricks, CNBC's Jim Cramer, Ozempic, Novo, Mounjaro, George Frey, Lars Fruergaard Jorgensen, Wajahat Mehal, Tom Carper, Bill Cassidy of, We've, Camilla Sylvest, there's, Sylvest, Cowen, What's, It's, Mike Mason, Amgen, Emmanuel Papadakis Organizations: Novo Nordisk, Pfizer, Amgen, Barclays, Nordisk, Drug Administration, Mounjaro, SVB Securities, Food and Drug Administration, Pharmacy, Reuters Novo, Novo, Wegovy, European Union, Medicare, Yale School, Metabolic, Congressional Black Caucus, CDC, pharma, American Medical Association, , Big Pharma, American Diabetes Association, Deutsche Bank Locations: Lilly, Denmark, Provo , Utah, U.S, European, Delaware, Bill Cassidy of Louisiana, Novo, Kalundborg, Hillerød, Boone County , Indiana

☆ Eli Lilly says obesity drug helped boost weight loss to 26%, highest seen in late-stage trials
▼ + stars: | 2023-07-27 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Mike Blake | ReutersTrial resultsOne trial, called Surmount-4, evaluated more than 600 people over two periods. Patients took tirzepatide for 36 weeks and achieved 21.1% weight loss on average. Overall, patients who stayed on the drug lost 26% of their weight on average after 88 weeks. The experimental obesity drug helped patients lose around 24% of their weight, setting a new bar for weight loss in mid-stage clinical trials. A selection of injector pens for the Wegovy weight loss drug are shown in this photo illustration in Chicago, Illinois, March 31, 2023.

Persons: Eli Lilly, Mike Blake, tirzepatide, Dr, Jeff Emmick, Eli Lilly's, Eli Lilly's tirzepatide, Jim Vondruska Organizations: Wegovy Locations: San Diego , California, Chicago , Illinois

☆ TC Energy to sell 40% in Columbia gas transmission systems for $4 bln
▼ + stars: | 2023-07-24 | by ( ) www.reuters.com time to read: +1 min

July 24 (Reuters) - Canada's TC Energy (TRP.TO), best known for its Keystone oil pipeline, will divest a 40% interest in its Columbia Gas Transmission and Columbia Gulf Transmission pipelines for C$5.2 billion ($3.95 billion) to Global Infrastructure Partners (GIP). TC was on course to deliver on its target to divest C$5 billion of assets by the end of the year, CEO François Poirier said in April. Columbia Gas and Columbia Gulf will be held in a new joint venture partnership and TC will remain the operator under the deal, which is expected to close in the fourth quarter. The pipelines span more than 15,000 miles and deliver a substantial portion of daily U.S. natural gas demand, including about 20% of U.S. liquefied natural gas (LNG) export supply, according to TC Energy. ($1 = 1.3180 Canadian dollars)Reporting by Arshreet Singh; Editing by Shounak Dasgupta and Sriraj KalluvilaOur Standards: The Thomson Reuters Trust Principles.

Persons: François Poirier, TotalEnergies, Arshreet Singh, Shounak Dasgupta, Sriraj Organizations: Canada's TC Energy, Keystone, Columbia, Transmission, Global Infrastructure Partners, TC, Columbia Gas, GIP, TC Energy, Thomson Locations: The Calgary , Alberta, British Columbia, U.S, Rio Grande

☆ The options for weight loss treatment are about to explode. These are the companies investors need to know
▼ + stars: | 2023-07-03 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +14 min

Wegovy was approved as an obesity treatment in June 2021 , but Ozempic, a Type 2 diabetes treatment, has been used off-label for weight loss. Mounjaro uses GLP-1 and gastric inhibitory polypeptide, or GIP, to help patients lose weight. Eli Lilly's oral drug, orforglipron, has an even better profile . They also could be helpful in assisting patients in maintaining weight loss after they've used the injectable versions, he said. Some have highlighted that oral drugs also may be more manageable for patients who can't handle the idea of giving themselves a once-a-week injection.

Persons: Eli Lilly, we're, Jonathan Wolleben, Wegovy, Lilly's tirzepatide, It's, Mounjaro, Wolleben, Eli Lilly's tirzepatide, Lilly, —, Novo, Eli, it's, they've, FactSet, Altimmune's pemvidutide, Morgan Stanley, Mark Purcell, Purcell, Graig Suvannavejh, Suvannavejh, Roth, Dylan Dupuis, Dupuis, Trung Huynh, Goldman Sachs, Chris Shibutani, Shibutani Organizations: Novo Nordisk, JMP Securities, Citizens Company, Nordisk's Ozempic, Food and Drug Administration, Nordisk, Novo, Zealand Pharma, Shandong Suncadia, GSBR, Biosciences, Fujian Shengdi Pharmaceutical, Mizuho Securities, Terns Pharmaceuticals, American Diabetes Association, Viking Therapeutics, Pfizer, Credit Suisse, AstraZeneca, Therapeutics, Medicare, Medicaid, CNBC Pro's Locations: Danish, Shandong, Fujian, Viking

☆ Here's a list of weight-loss drugs in development and awaiting approval to take on Ozempic
▼ + stars: | 2023-06-28 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +10 min

The company's chief rival, Denmark-based Novo Nordisk (NVO), also published promising data on drugs in its pipeline, including its own oral weight-loss treatment. Other pharmaceutical companies are racing to compete with Novo Nordisk and Eli Lilly, including Amgen (AMGN) and Pfizer (PFE). Barclays on Tuesday projected Eli Lilly's three leading obesity-and-diabetes drugs could generate nearly $49 billion in combined sales in 2030. Eli Lilly Eli Lilly has multiple drugs in development that fall under the GLP-1 umbrella in various stages of clinical development. Novo Nordisk Novo Nordisk currently dominates the market for GLP-1 drugs, with three products in the class on the U.S. market already: Ozempic, Wegovy and Rybelsus.

Persons: It's, Eli Lilly, Eli Lilly's, retatrutide, Lilly, there's, Lilly's, Geoff Meacham, Eli Lilly Eli Lilly, Jim Cramer, Evan David Seigerman, —, — Morgan Stanley, Wegovy, Rybelsus, Jim Cramer's, Jim, Mike Segar Organizations: Club, Novo Nordisk, New England, of Medicine, American Diabetes Association, Pfizer, Reuters, Barclays, Bank of America, CNBC, JPMorgan, Drug Administration, Equity, BMO Capital, Novo Nordisk Novo Nordisk, GLP, FDA, Nordisk, Company Locations: San Diego, Denmark, GLP, It's, Novo, Novo Nordisk's, Branchburg , New Jersey

☆ Eli Lilly's weight loss drugs trounce sky-high expectations, boosting the stock
▼ + stars: | 2023-06-27 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +5 min

What's more, some showed no signs their weight loss was leveling off, suggesting they could continue to shed pounds. (Both use semaglutide, but Ozempic is marketed as a type 2 diabetes treatment, while Wegovy is primarily for weight loss.) Bank of America's Geoff Meacham said retatrutide "exceeded expectations" for weight loss. "This is important, as while the overall 22.4% weight loss was impressive, looking at men and women separately, weight loss was 21.9% and 28.5%, respectively, with the slope in females not yet plateauing. Schott also described the weight loss as "impressive" and said it will likely compare favorably with Novo's next-generation drug CagriSema, which is expected to show weight loss of more than 25% when it releases its next update.

Persons: Eli Lilly, What's, Lilly, Lilly's, Carter Gould, Gould, orforglipron, Bank of America's Geoff Meacham, retatrutide, Meacham, Chris Schott, Schott, Novo's, Evan David Seigerman, Seigerman, Morgan Stanley, Terence Flynn, — CNBC's Michael Bloom Organizations: American Diabetes Association, Wall, Novo Nordisk, Barclays, Bank of America's, JPMorgan, Lilly, BMO Capital, Indianapolis, ~$ Locations: Novo

☆ Eli Lilly experimental obesity drug helped patients lose up to 24% of their weight, study says
▼ + stars: | 2023-06-26 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Eli Lilly ’s experimental drug helped patients lose up to 24% of their weight after almost a year, the highest reduction seen in the obesity treatment space to date, according to new mid-stage clinical trial results released Monday. The trial's researchers said average weight loss did not appear to plateau after 48 weeks, suggesting a longer study could show even more. Eli Lilly’s other obesity drug Mounjaro, which is approved for type 2 diabetes, has helped patients lose up to 21% of their weight in clinical trials. Novo Nordisk’ s Wegovy, cleared for weight loss, has shown up to 15% weight loss in trials. But Wegovy only mimics one hunger-regulating hormone called GLP-1, while Mounjaro mimics GLP-1 and another hormone called GIP.

Persons: Eli Lilly ’, Eli Lilly, Eli Lilly’s retatrutide, ” Michael Weintraub, Eli Lilly’s, Eli Lilly's retatrutide Organizations: NYU Langone Health, Novo Nordisk

☆ Lilly experimental 'triple G' obesity drug leads to 24.2% weight loss in trial
▼ + stars: | 2023-06-26 | by ( Deena Beasley | ) www.reuters.com time to read: +2 min

Companies Eli Lilly and Co FollowJune 26 (Reuters) - Eli Lilly (LLY.N) on Monday said a mid-stage trial of its next-generation obesity drug candidate "triple G" showed that it led to weight loss of up to 24.2% after 48 weeks, surpassing results seen with other weight loss drugs. Lilly's Mounjaro, which is awaiting U.S. regulatory approval for treatment of obesity, targets GLP-1 as well as a second obesity-related hormone called GIP. Retatrutide targets GLP-1, GIP and the body's receptors for a third hormone, glucagon. Given the three targets, Lilly has nicknamed the drug triple G.The company reported last year that a trial of Mounjaro in people who were obese or overweight found it led to weight loss of 22.5% after 72 weeks. Lilly is conducting longer-duration phase 3 trials of retatrutide to see if weight loss might be further improved.

Persons: Eli Lilly, Lilly's, Lilly, ” Dan Skovronsky, Deena Beasley, Deepa Babington, Cynthia Osterman Organizations: American Diabetes Association, New England, of Medicine, Thomson Locations: San Diego

Eli Lilly also is expected to present data on another weight-loss drug called orforglipron, which patients take orally instead of through an injection. Retatrutide, Mounjaro and weight-loss drug Wegovy, produced by rival Novo Nordisk (NVO), are all injectable. But if the data were to fall short of expectations, the analysts don't foresee much downside to J & J shares. However, with JNJ-2113, Morgan Stanley noted that J & J management has touted its efficacy profile "without the baggage of a JAK label." J & J has consistently denied those accusations.

Persons: Eli Lilly, Johnson, Morgan Stanley —, Eli Lilly Eli Lilly, Morgan Stanley, Eli Lilly's Mounjaro, Mounjaro, Lilly's, retatrutide, hasn't, haven't, Jim Cramer's, Jim Cramer, Jim, AJ Mast Organizations: American Diabetes Association, Novo Nordisk, U.S . Food, Drug Administration, Pfizer, Novo Nordisk's, Johnson, American Academy of Dermatology, topline, J's, LTL Management, CNBC, Bloomberg, Getty, & ' $ Locations: U.S, Novo, Indianapolis , Indiana

☆ How promising are new drugs to treat obesity?
▼ + stars: | 2023-05-05 | by ( Katia Hetter | ) edition.cnn.com time to read: +8 min

CNN —The pharmaceutical company Eli Lilly announced last week that a medication developed to treat diabetes, tirzepatide, also had a substantial effect on reducing weight. Another pharmaceutical company, Novo Nordisk, manufactures the medication semaglutide, which the FDA has already approved to treat diabetes under the brand name Ozempic and to treat obesity under the brand name Wegovy. How promising are they to treat obesity? CNN: How promising are these drugs to treat obesity? It is really important to treat obesity as the disease that it is — and having effective medications to do so is crucial.

☆ Obesity is a chronic disease. It's why treating it will be so profitable unless payers push back
▼ + stars: | 2023-04-30 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +9 min

Lilly manufactures tirzepatide, which is sold under the brand name Mounjaro as a type 2 diabetes treatment. It's the chronic nature of obesity that will make these drugs so profitable, analysts have said. Huynh increased his target due to higher expectations for Mounjaro sales this year. Huynh boosted his prediction for the drug's sales this year to $3.7 billion from an prior estimate of $2.7 billion. "$48 billion is a monster number," Holz said, referring to an annual sales estimate that Bank of America has floated for future Mounjaro sales.

CDP is seeking to finalise its bid after U.S. investment firm KKR (KKR.N) last week filed its own offer for the same Telecom Italia (TIM) asset. Two sources familiar with the matter told Reuters KKR's approach valued the venture at about 20 billion euros ($21.4 billion). Prime Minister Giorgia Meloni repeatedly said her government wants to secure public control of TIM's network. But there is no common ground yet within her administration on how to reach such a goal and it was no clear whether a CDP bid would receive the blessing of the Treasury. Economy Minister Giancarlo Giorgetti believes Rome has "multiple options" to put TIM's network under strategic government control, a separate source said, without elaborating.

☆ Eli Lilly investors spooked by weak Mounjaro sales, but it's the obesity drug approval that will unlock its value
▼ + stars: | 2023-02-02 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +5 min

Lilly said slightly more than 50% of commercial and Part D subscribers have access to the drug via their insurance plans. But new classes of weight loss medications are helping to change this mindset. Still, legislation will be necessary to get coverage of Mounjaro for obesity and overweight treatment by Medicare plans. By law, these plans are banned from paying for weight loss medications. Wegovy and Mounjaro One encouraging sign: Lilly competitor Novo Nordisk has gained access to more than 80% of insurance company formularies for their obesity treatment, Wegovy.

☆ Amgen says experimental obesity drug has promising durability
▼ + stars: | 2022-12-03 | by ( Deena Beasley | ) www.reuters.com time to read: +3 min

LOS ANGELES, Dec 3 (Reuters) - Amgen Inc's (AMGN.O) experimental obesity drug demonstrated promising durability trends in an early trial, paving the way for a larger mid-stage study early next year, company officials said ahead of a data presentation on Saturday. The small Phase I trial found that patients maintained their weight loss for 70 days after receiving the highest tested dose of the injected drug, currently known as AMG133. Amgen shares have gained about 5% since the company said on Nov. 7 that 12 weeks of trial treatment at the highest monthly dose of AMG133 resulted in mean weight loss of 14.5%. Patients treated with AMG133 did have side effects including nausea and vomiting, but most cases were mild and resolved within a couple of days after the first dose, Amgen said. The drug was developed from work at Amgen to identify genetic signals associated with lower fat mass and body weight, and also healthy metabolic profiles, explained Saptarsi Haldar, head of cardiovascular metabolic discovery at Amgen.

☆ Atlantia set to be delisted as buyout bid reaches 90% threshold
▼ + stars: | 2022-11-24 | by ( Hadeel Al Sayegh | ) www.reuters.com time to read: +1 min

MILAN, Nov 24 (Reuters) - A buyout offer launched by the Benetton family and U.S. investment fund Blackstone (BX.N) for Italy's Atlantia (ATL.MI) has reached the 90% threshold for the deal to proceed and trigger the company's delisting, the bidders said on Thursday. The bid initially failed to reach the threshold but was then reopened for another five days and closes on Friday. The bidders' vehicle named Schema Alfa said in a statement the planned delisting would happen "as soon as possible in the following weeks". The enterprise value of the deal was around 54 billion euros ($56.32 billion) based on Atlantia's debt level at the end of last year. Atlantia shares closed at 22.95 euros on Wednesday, just below the 23 euros per share Schema Alfa is offering to pay.

Search resuls for: "GIP"

25 mentions found